Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-10-16 4:35 pm Purchase | 13D | Squarespace Inc. SQSP | Farallon Capital Partners L.P. | 5,600,000 6.1% | 5,600,000 (New Position) | View |
2024-05-17 4:58 pm Purchase | 13G | NANOSTRING TECHNOLOGIES INC CO NSTGQ | Farallon Capital Partners L.P. | 4,391,941 9.1% | 4,391,941 (New Position) | View |
2024-05-08 4:11 pm Purchase | 13D | EXELIXIS INC. EXEL | Farallon Capital Partners L.P. | 26,769,500 9.2% | 909,500 (+3.52%) | View |
2024-02-14 09:33 am Purchase | 13G | Forte Biosciences Inc. FBRX | Farallon Capital Partners L.P. | 3,793,497 9.9% | 5,861 (+0.15%) | View |
2024-02-12 5:11 pm Sale | 13G | Revolution Medicines Inc. RVMD | Farallon Capital Partners L.P. | 6,750,204 4.1% | -12,276 (-0.18%) | View |
2024-02-12 3:38 pm Sale | 13G | Beam Therapeutics Inc. BEAM | Farallon Capital Partners L.P. | 4,105,753 5% | -7,716 (-0.19%) | View |
2024-02-08 11:39 am Purchase | 13G | AGIOS PHARMACEUTICALS INC. AGIO | Farallon Capital Partners L.P. | 4,167,602 7.5% | 206,000 (+5.20%) | View |
2024-02-06 10:16 am Purchase | 13G | Aramark ARMK | Farallon Capital Partners L.P. | 16,899,254 6.4% | 1,518,185 (+9.87%) | View |
2024-02-05 5:28 pm Unchanged | 13D | CAZOO GROUP LTD OCT 2023 CZOOF | Farallon Capital Partners L.P. | 714,240 14.6% | 0 (Unchanged) | View |
2024-02-05 11:22 am Sale | 13G | SWIFTMERGE ACQUISITION CORP WT IVCPW | Farallon Capital Partners L.P. | 525,000 9% | -1,680,000 (-76.19%) | View |
2024-02-02 09:19 am Purchase | 13G | PROTAGONIST THERAPEUTICS INC C PTGX | Farallon Capital Partners L.P. | 5,765,109 9.99% | 710,007 (+14.05%) | View |
2024-02-01 3:50 pm Purchase | 13G | Savara Inc SVRA | Farallon Capital Partners L.P. | 14,326,911 9.99% | 2,794,289 (+24.23%) | View |
2024-01-30 1:38 pm Sale | 13G | BERENSON ACQUISITION CORP I CL BACA | Farallon Capital Partners L.P. | 413,113 9.9% | -2,249,387 (-84.48%) | View |
2024-01-30 11:23 am Purchase | 13G | Longboard Pharmaceuticals Inc. LBPH | Farallon Capital Partners L.P. | 2,205,990 9.99% | 788,073 (+55.58%) | View |
2024-01-26 09:11 am Purchase | 13G | ENANTA PHARMACEUTICALS INC ENTA | Farallon Capital Partners L.P. | 2,025,000 9.6% | 475,000 (+30.65%) | View |
2024-01-25 08:28 am Sale | 13G | Forest Road Acquisition Corp. II FRXB | Farallon Capital Partners L.P. | 0 0% | -400,000 (Position Closed) | View |
2024-01-24 10:07 am Sale | 13G | Tectonic Therapeutic Inc. TECX | Farallon Capital Partners L.P. | 0 0% | -3,116,000 (Position Closed) | View |
2024-01-22 09:02 am Purchase | 13G | ELEVATION ONCOLOGY INC ELEV | Farallon Capital Partners L.P. | 3,100,000 7.3% | 3,100,000 (New Position) | View |
2024-01-19 09:05 am Sale | 13G | Disruptive Acquisition Corp I DISA | Farallon Capital Partners L.P. | 0 0% | -1,400,000 (Position Closed) | View |
2024-01-18 08:58 am Sale | 13G | ARYA Sciences Acquisition Corp IV ARYD | Farallon Capital Partners L.P. | 200,000 4.8% | -600,000 (-75.00%) | View |